Neuroscience Bulletin

, Volume 30, Issue 6, pp 923–935 | Cite as

Humanin attenuates Alzheimer-like cognitive deficits and pathological changes induced by amyloid β-peptide in rats

  • Gao-Shang Chai
  • Dong-Xiao Duan
  • Rong-Hong Ma
  • Jian-Ying Shen
  • Hong-Lian Li
  • Zhi-Wei Ma
  • Yu Luo
  • Lu Wang
  • Xin-Hua Qi
  • Qun Wang
  • Jian-Zhi Wang
  • Zelan Wei
  • Darrell D. Mousseau
  • Li Wang
  • Gongping Liu
Original Article


Amyloid β-peptide (Aβ) has been implicated as a key molecule in the neurodegenerative cascades of Alzheimer’s disease (AD). Humanin (HN) is a secretory peptide that inhibits the neurotoxicity of Aβ. However, the mechanism(s) by which HN exerts its neuroprotection against Aβ-induced ADlike pathological changes and memory deficits are yet to be completely defined. In the present study, we provided evidence that treatment of rats with HN increases the number of dendritic branches and the density of dendritic spines, and upregulates pre- and post-synaptic protein levels; these effects lead to enhanced long-term potentiation and amelioration of the memory deficits induced by Aβ1–42. HN also attenuated Aβ1–42-induced tau hyperphosphorylation, apparently by inhibiting the phosphorylation of Tyr307 on the inhibitory protein phosphatase-2A (PP2A) catalytic subunit and thereby activating PP2A. HN also inhibited apoptosis and reduced the oxidative stress induced by Aβ1–42. These findings provide novel mechanisms of action for the ability of HN to protect against Aβ1–42-induced AD-like pathological changes and memory deficits.


Humanin amyloid-beta Alzheimer’s disease tau apoptosis 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. [1]
    Alonso AD, Grundke-Iqbal I, Barra HS Iqbal K. Abnormal phosphorylation of tau and the mechanism of Alzheimer neurofibrillary degeneration: sequestration of microtubule-associated proteins 1 and 2 and the disassembly of microtubules by the abnormal tau. Proc Natl Acad Sci U S A 1997, 94: 298–303.PubMedCentralPubMedCrossRefGoogle Scholar
  2. [2]
    Ramsden M, Kotilinek L, Forster C, Paulson J, McGowan E, SantaCruz K, et al. Age-dependent neurofibrillary tangle formation, neuron loss, and memory impairment in a mouse model of human tauopathy (P301L). J Neurosci 2005, 25, 10637–10647.PubMedCrossRefGoogle Scholar
  3. [3]
    Terry RD. Cell death or synaptic loss in Alzheimer disease. J Neuropathol Exp Neurol 2000, 59: 1118–1119.PubMedGoogle Scholar
  4. [4]
    Paulson JB, Ramsden M, Forster C, Sherman MA, McGowan E, Ashe KH. Amyloid plaque and neurofibrillary tangle pathology in a regulatable mouse model of Alzheimer’s disease. Am J Pathol 2008, 173: 762–772.PubMedCentralPubMedCrossRefGoogle Scholar
  5. [5]
    Mount C, Downton C. Alzheimer disease: progress or profit? Nat Med 2006, 12: 780–784.PubMedCrossRefGoogle Scholar
  6. [6]
    Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science 2002, 297: 353–356.PubMedCrossRefGoogle Scholar
  7. [7]
    Sisodia SS, St GP. gamma-Secretase, Notch, Abeta and Alzheimer’s disease: where do the presenilins fit in? Nat Rev Neurosci 2002, 3: 281–290.PubMedCrossRefGoogle Scholar
  8. [8]
    Gotz J, Chen F, van Dorpe J, Nitsch RM. Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. Science 2001, 293: 1491–1495.PubMedCrossRefGoogle Scholar
  9. [9]
    Lippa CF, Nee LE, Mori H, St GP. Abeta-42 deposition precedes other changes in PS-1 Alzheimer’s disease. Lancet 1998, 352: 1117–1118.PubMedCrossRefGoogle Scholar
  10. [10]
    Roher AE, Lowenson JD, Clarke S, Woods AS, Cotter RJ, Gowing E, et al. beta-Amyloid-(1–42) is a major component of cerebrovascular amyloid deposits: implications for the pathology of Alzheimer disease. Proc Natl Acad Sci U S A 1993, 90: 10836–10840.PubMedCentralPubMedCrossRefGoogle Scholar
  11. [11]
    Guo H, Albrecht S, Bourdeau M, Petzke T, Bergeron C, LeBlanc AC. Active caspase-6 and caspase-6-cleaved tau in neuropil threads, neuritic plaques, and neurofibrillary tangles of Alzheimer’s disease. Am J Pathol 2004, 165: 523–531.PubMedCentralPubMedCrossRefGoogle Scholar
  12. [12]
    McPhie DL, Coopersmith R, Hines-Peralta A, Chen Y, Ivins KJ, Manly S, et al. DNA synthesis and neuronal apoptosis caused by familial Alzheimer disease mutants of the amyloid precursor protein are mediated by the p21 activated kinase PAK3. J Neurosci 2003, 23: 6914–6927.PubMedGoogle Scholar
  13. [13]
    Yu W, Mechawar N, Krantic S, Quirion R. Evidence for the involvement of apoptosis-inducing factor-mediated caspase-independent neuronal death in Alzheimer disease. Am J Pathol 2010, 176: 2209–2218.PubMedCentralPubMedCrossRefGoogle Scholar
  14. [14]
    Kukar T, Murphy MP, Eriksen JL, Sagi SA, Weggen S, Smith TE, et al. Diverse compounds mimic Alzheimer disease-causing mutations by augmenting Abeta42 production. Nat Med 2005, 11: 545–550.PubMedCrossRefGoogle Scholar
  15. [15]
    Moonis M, Swearer JM, Dayaw MP, St GP, Rogaeva E, Kawarai T, et al. Familial Alzheimer disease: decreases in CSF Abeta42 levels precede cognitive decline. Neurology 2005, 65: 323–325.PubMedCrossRefGoogle Scholar
  16. [16]
    Cramer PE, Cirrito JR, Wesson DW, Lee CY, Karlo JC, Zinn AE, et al. ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models. Science 2012, 335: 1503–1506PubMedCentralPubMedCrossRefGoogle Scholar
  17. [17]
    Hashimoto Y, Ito Y, Niikura T, Shao Z, Hata M, Oyama F, et al. Mechanisms of neuroprotection by a novel rescue factor humanin from Swedish mutant amyloid precursor protein. Biochem Biophys Res Commun (2001a), 283: 460–468.PubMedCrossRefGoogle Scholar
  18. [18]
    Nishimoto I, Matsuoka M, Niikura T. Unravelling the role of Humanin. Trends Mol Med 2004, 10: 102–105.PubMedCrossRefGoogle Scholar
  19. [19]
    Chiba T, Yamada M, Hashimoto Y, Sasabe J, Kita Y, Terashita K, et al. Development of a femtomolar-acting humanin derivative named colivelin by attaching activity-dependent neurotrophic factor to its N terminus: characterization of colivelin-mediated neuroprotection against Alzheimer’s disease-relevant insults in vitro and in vivo. J Neurosci 2005, 25: 10252–10261.PubMedCrossRefGoogle Scholar
  20. [20]
    Hashimoto Y, Niikura T, Tajima H, Yasukawa T, Sudo H, Ito Y, et al. A rescue factor abolishing neuronal cell death by a wide spectrum of familial Alzheimer’s disease genes and Abeta. Proc Natl Acad Sci U S A 2001b, 98: 6336–6341.PubMedCentralPubMedCrossRefGoogle Scholar
  21. [21]
    Hashimoto Y, Niikura T, Ito Y, Sudo H, Hata M, Arakawa E, et al. Detailed characterization of neuroprotection by a rescue factor humanin against various Alzheimer’s disease-relevant insults. J Neurosci 2001c, 21: 9235–9245.PubMedGoogle Scholar
  22. [22]
    Ikonen M, Liu B, Hashimoto Y, Ma L, Lee KW, Niikura T, et al. Interaction between the Alzheimer’s survival peptide humanin and insulin-like growth factor-binding protein 3 regulates cell survival and apoptosis. Proc Natl Acad Sci U S A 2003, 100: 13042–13047.PubMedCentralPubMedCrossRefGoogle Scholar
  23. [23]
    Kariya S, Takahashi N, Ooba N, Kawahara M, Nakayama H, Ueno S. Humanin inhibits cell death of serum-deprived PC12h cells. Neuroreport 2002, 13: 903–907.PubMedCrossRefGoogle Scholar
  24. [24]
    Wang D, Li H, Yuan H, Zheng M, Bai C, Chen L, et al. Humanin delays apoptosis in K562 cells by downregulation of P38 MAP kinase. Apoptosis 2005, 10: 963–971.PubMedCrossRefGoogle Scholar
  25. [25]
    Pike CJ, Nguyen TV, Ramsden M, Yao M, Murphy MP, Rosario ER. Androgen cell signaling pathways involved in neuroprotective actions. Horm Behav 2008, 53: 693–705.PubMedCentralPubMedCrossRefGoogle Scholar
  26. [26]
    Frautschy SA, Baird A, Cole GM. Effects of injected Alzheimer beta-amyloid cores in rat brain. Proc Natl Acad Sci U S A 1991, 88: 8362–8366.PubMedCentralPubMedCrossRefGoogle Scholar
  27. [27]
    Morris R. Developments of a water-maze procedure for studying spatial learning in the rat. J Neurosci Methods 1984, 11: 47–60.PubMedCrossRefGoogle Scholar
  28. [28]
    Tu W, Xu X, Peng L, Zhong X, Zhang W, Soundarapandian MM, et al. DAPK1 interaction with NMDA receptor NR2B subunits mediates brain damage in stroke. Cell 2010, 140: 222–234.PubMedCentralPubMedCrossRefGoogle Scholar
  29. [29]
    Chai GS, Jiang X, Ni ZF, Ma ZW, Xie AJ, Cheng XS, et al. Betaine attenuates Alzheimer-like pathological changes and memory deficits induced by homocysteine. J Neurochem 2013, 124: 388–396.PubMedCrossRefGoogle Scholar
  30. [30]
    Zhu LQ, Liu D, Hu J, Cheng J, Wang SH, Wang Q, et al. GSK-3 beta inhibits presynaptic vesicle exocytosis by phosphorylating P/Q-type calcium channel and interrupting SNARE complex formation. J Neurosci 2010, 30: 3624–3633.PubMedCrossRefGoogle Scholar
  31. [31]
    Liu SJ, Zhang JY, Li HL, Fang ZY, Wang Q, Deng HM, et al. Tau becomes a more favorable substrate for GSK-3 when it is prephosphorylated by PKA in rat brain. J Biol Chem 2004, 279, 50078–50088.PubMedCrossRefGoogle Scholar
  32. [32]
    Yang Y, Shu X, Liu D, Shang Y, Wu Y, Pei L, et al. EPAC Null Mutation Impairs Learning and Social Interactions via Aberrant Regulation of miR-124 and Zif268 Translation. Neuron 2012, 73: 774–788.PubMedCentralPubMedCrossRefGoogle Scholar
  33. [33]
    Iqbal K, Grundke-Iqbal I, Smith AJ, George L, Tung YC, Zaidi, T. Identification and localization of a tau peptide to paired helical filaments of Alzheimer disease. Proc Natl Acad Sci U S A 1989, 86: 5646–5650.PubMedCentralPubMedCrossRefGoogle Scholar
  34. [34]
    Liu F, Liang Z, Gong CX. Hyperphosphorylation of tau and protein phosphatases in Alzheimer disease. Panminerva Med 2006, 48: 97–108.PubMedGoogle Scholar
  35. [35]
    Butterfield DA, Drake J, Pocernich C, Castegna A. Evidence of oxidative damage in Alzheimer’s disease brain: central role for amyloid beta-peptide. Trends Mol Med 2001, 7: 548–554.PubMedCrossRefGoogle Scholar
  36. [36]
    Reddy PH. Amyloid precursor protein-mediated free radicals and oxidative damage: implications for the development and progression of Alzheimer’s disease. J Neurochem 2006, 96: 1–13.PubMedCrossRefGoogle Scholar
  37. [37]
    We Z, Song MS, MacTavish D, Jhamandas JH, Kar S. Role of calpain and caspase in beta-amyloid-induced cell death in rat primary septal cultured neurons. Neuropharmacology 2008, 54: 721–733CrossRefGoogle Scholar
  38. [38]
    Wilkinson BL, Cramer PE, Varvel NH, Reed-Geaghan E, Jiang Q, Szabo A, et al. Ibuprofen attenuates oxidative damage through NOX2 inhibition in Alzheimer’s disease. Neurobiol Aging 2012, 33: 121–197.CrossRefGoogle Scholar
  39. [39]
    Murray IV, Sindoni ME, Axelsen PH. Promotion of oxidative lipid membrane damage by amyloid beta proteins. Biochemistry-Us 2005, 44: 12606–12613.CrossRefGoogle Scholar
  40. [40]
    Bachar AR, Scheffer L, Schroeder AS, Nakamura HK, Cobb LJ, Oh YK, et al. Humanin is expressed in human vascular walls and has a cytoprotective effect against oxidized LDL-induced oxidative stress. Cardiovasc Res 2010, 88: 360–366.PubMedCentralPubMedCrossRefGoogle Scholar
  41. [41]
    Mamiya T, Ukai M. [Gly(14)]-Humanin improved the learning and memory impairment induced by scopolamine in vivo. Br J Pharmacol 2001, 134: 1597–1599.PubMedCentralPubMedCrossRefGoogle Scholar
  42. [42]
    Niikura T, Sidahmed E, Hirata-Fukae C, Aisen PS, Matsuoka Y. A humanin derivative reduces amyloid beta accumulation and ameliorates memory deficit in triple transgenic mice. PLoS One 2011, 6: e16259.PubMedCentralPubMedCrossRefGoogle Scholar
  43. [43]
    Richter-Levin G, Segal M. The effects of serotonin depletion and raphe grafts on hippocampal electrophysiology and behavior. J Neurosci 1991, 11: 1585–1596.PubMedGoogle Scholar
  44. [44]
    Greengard P, Valtorta F, Czernik AJ, Benfenati F. Synaptic vesicle phosphoproteins and regulation of synaptic function. Science 1993, 259: 780–785.PubMedCrossRefGoogle Scholar
  45. [45]
    Pieribone VA, Shupliakov O, Brodin L, Hilfiker-Rothenfluh S, Czernik AJ, Greengard P. Distinct pools of synaptic vesicles in neurotransmitter release. Nature 1995, 375: 493–497.PubMedCrossRefGoogle Scholar
  46. [46]
    Slutsky I, Abumaria N, Wu LJ, Huang C, Zhang L, Li B, et al. Enhancement of learning and memory by elevating brain magnesium. Neuron 2010, 65: 165–177.PubMedCrossRefGoogle Scholar
  47. [47]
    Grundke-Iqbal I, Iqbal K, Tung YC, Quinlan M, Wisniewski HM, Binder LI. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci U S A 1986, 83: 4913–4917.PubMedCentralPubMedCrossRefGoogle Scholar
  48. [48]
    Wang JZ, Gong CX, Zaidi T, Grundke-Iqbal I, Iqbal K. Dephosphorylation of Alzheimer paired helical filaments by protein phosphatase-2A and -2B. J Biol Chem 1995, 270: 4854–4860.PubMedCrossRefGoogle Scholar
  49. [49]
    Tian Q, Wang J. Role of serine/threonine protein phosphatase in Alzheimer’s disease. Neurosignals 2002, 11: 262–269.PubMedCrossRefGoogle Scholar
  50. [50]
    Jung SS, Van Nostrand WE. Humanin rescues human cerebrovascular smooth muscle cells from Abeta-induced toxicity. J Neurochem 2003, 84: 266–272.PubMedCrossRefGoogle Scholar
  51. [51]
    Hashimoto Y, Suzuki H, Aiso S, Niikura T, Nishimoto I, Matsuoka M. Involvement of tyrosine kinases and STAT3 in Humanin-mediated neuroprotection. Life Sci 2005, 77: 3092–3104.PubMedCrossRefGoogle Scholar
  52. [52]
    Caricasole A, Bruno V, Cappuccio I, Melchiorri D, Copani A, Nicoletti F. A novel rat gene encoding a Humanin-like peptide endowed with broad neuroprotective activity. FASEB J 2002, 16: 1331–1333.PubMedGoogle Scholar
  53. [53]
    Guo B, Zhai D, Cabezas E, Welsh K, Nouraini S, Satterthwait AC, et al. Humanin peptide suppresses apoptosis by interfering with Bax activation. Nature 2003, 423: 456–461.PubMedCrossRefGoogle Scholar
  54. [54]
    Butterfield DA, Bush AI. Alzheimer’s amyloid beta-peptide (1–42): involvement of methionine residue 35 in the oxidative stress and neurotoxicity properties of this peptide. Neurobiol Aging 2004, 25: 563–568.PubMedCrossRefGoogle Scholar
  55. [55]
    Mattson MP. Pathways towards and away from Alzheimer’s disease. Nature 2004, 430: 631–639.PubMedCentralPubMedCrossRefGoogle Scholar
  56. [56]
    Hashimoto Y, Niilura T, Jajima H, Yasukawa T, Sudo H, Ito Y, et al. A rescue factor abolishing neuronal cell death by a wide spectrum of familial Alzheimer’s disease genes and Abeta. Proc Natl Acad Sci U S A 2001, 98: 6336–6341.PubMedCentralPubMedCrossRefGoogle Scholar
  57. [57]
    Guo B, Zhai D, Cabezas E, Welsh K, Nouraini S, Satterthwait AC, et al. Humanin peptide suppresses apoptosis by interfering with Bax activation. Nature 2003, 423: 456–461.PubMedCrossRefGoogle Scholar
  58. [58]
    Hashimoto Y, Niilura T, Chiba T, Tsukamoto E, Kadowaki H, Nishitoh H, et al. The cytoplasmic domain of Alzheimer’s amyloid-b protein precursor causes sustained ASK1/JNK mediated neurotoxic signal via dimerization. J Pharmacol Exp Ther 2003, 306: 889–902.PubMedCrossRefGoogle Scholar
  59. [59]
    Hashimoto Y, Kurita M, Aiso S, Nishimoto I, Matsuoka M. Humanin inhibits neuronal cell death by interacting with a cytokine receptor complex or complexes involving CNTF receptor alpha/WSX-1/gp130. Mol Biol Cell 2009, 20: 2864–2873.PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© Shanghai Institutes for Biological Sciences, CAS and Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Gao-Shang Chai
    • 1
    • 2
  • Dong-Xiao Duan
    • 1
    • 3
  • Rong-Hong Ma
    • 4
  • Jian-Ying Shen
    • 5
  • Hong-Lian Li
    • 5
  • Zhi-Wei Ma
    • 1
  • Yu Luo
    • 1
  • Lu Wang
    • 1
  • Xin-Hua Qi
    • 6
  • Qun Wang
    • 1
  • Jian-Zhi Wang
    • 1
  • Zelan Wei
    • 7
  • Darrell D. Mousseau
    • 7
  • Li Wang
    • 8
  • Gongping Liu
    • 1
  1. 1.Department of Pathophysiology, Key Laboratory of Neurological Diseases of Chinese Ministry of Education, Tongji Medical CollegeHuazhong University of Science and TechnologyWuhanChina
  2. 2.Department of Basic Medical, Wuxi Medical SchoolJiangnan UniversityWuxiChina
  3. 3.Department of Physiology, Basic Medical CollegeZhengzhou UniversityZhengzhouChina
  4. 4.Department of Laboratory Medicine, Union HospitalHuazhong University of Science and TechnologyWuhanChina
  5. 5.Department of Histology and Embryology, Tongji Medical CollegeHuazhong University of Science and TechnologyWuhanChina
  6. 6.Affiliated Hospital of Hebei University of EngineeringHandanChina
  7. 7.Department of Psychiatry, College of MedicineUniversity of SaskatchewanSaskatoonCanada
  8. 8.Department of PathophysiologyHenan Medical CollegeZhengzhouChina

Personalised recommendations